5月1日 - ** 诺和诺德NOVOb.CO的股价上涨了6.5%，此前CVS HealthCVS.N称 (link)，该公司将把丹麦制药集团的Wegovy药品作为首选产品保留在美国符合报销条件的药品清单中。
** CVS的药房福利管理部门还计划将礼来公司（LLY.N）的减肥药Zepbound从名单中剔除。
** Nordnet公司分析师Per Hansen将公司股价的变动归因于CVS公司的交易，并补充说："也许诺和诺德公司正在慢慢走出冰冻期"。
** 诺和诺德的股价今年迄今下跌了26%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.